FRX Fennec Pharmaceuticals Inc
- 6.450
- +0.050+0.78%
Fennec Pharmaceuticals Inc News
Buy Rating Affirmed for Fennec Pharmaceuticals Amidst PEDMARK's Long-Term Growth Potential
H.C. Wainwright Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Cuts Target Price to $13
Maxim Group Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $22
Buy Rating for Fennec Pharmaceuticals Bolstered by Pedmark's Market Expansion and New Leadership
Fennec Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Announces Target Price $15
Capital One Financial Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Cuts Target Price to $15
Optimistic Buy Rating for Fennec Pharmaceuticals Amidst Pedmark's Market Expansion and Strong Financial Outlook
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating
Buy Rating Affirmed Amid Leadership Transition and Strong Growth Prospects for Fennec Pharmaceuticals
Capital One Financial Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $17
Buy Rating Affirmed for Fennec Pharmaceuticals Amidst Leadership Change and Market Opportunity Expansion
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating
Fennec Pharmaceuticals (FENC) Gets a Buy From Craig-Hallum
Fennec Pharmaceuticals Analyst Ratings
Fennec Pharmaceuticals Analyst Ratings
Maintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic Partnerships
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)
Fennec Pharmaceuticals (FENC) Gets a Buy From Capital One Financial
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook
No Data